Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

µ¦½º¸Þµ¥Åä¹ÌµòÀÇ ÀÓ»óÀûÀÎ »ç¿ë

Dexmedetomidine: Clinical use

´ëÇÑÄ¡°ú¸¶Ãë°úÇÐȸÁö 2013³â 13±Ç 4È£ p.161 ~ 166
À±Áö¿µ, ±èöȫ,
¼Ò¼Ó »ó¼¼Á¤º¸
À±Áö¿µ ( Yoon Ji-Young ) - ºÎ»ê´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø Ä¡°ú¸¶ÃëÅëÁõÇб³½Ç
±èöȫ ( Kim Cheul-Hong ) - ºÎ»ê´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø Ä¡°ú¸¶ÃëÅëÁõÇб³½Ç

Abstract


Dexmedetomidine is a potent alpha-2-adrenergic agonist, more selective than clonidine, with widespread actions on the mammalian brain. A large body of recent work supports its analgesia and sympatholytic properties. Dexmedetomidine is a useful medication with many clinical applications. The medication has shown efficacy in decreasing the need for opioids, benzodiazepines, propofol, and other sedative medications. Dexmedetomidine has been used effectively for sedation during invasive procedures and in the ICU. Short-term sedation has been shown to be safe in studies, although hypotension and bradycardia are the most significant side effects. Dexmedetomidine is emerging as an effective therapeutic agent in the management of a wide range of clinical conditions with an efficacious, safe profile.

Å°¿öµå

Bradycardia; Dexmedetomidine; Hypotension; Sedation

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI